Klivira
Request demo

Navigating Biktarvy Prior Authorization for Rheumatology Patients

While Biktarvy is an HIV medication, managing Biktarvy prior authorization for rheumatology patients with co-occurring conditions requires nuanced understanding of both infectious disease and rheumatology PA processes.

Revenue cycle directors and prior authorization teams face unique complexities when a patient's care spans multiple specialties. For rheumatology practices, ensuring timely approval for both rheumatology-specific treatments and medications for co-morbidities like HIV, such as Biktarvy, is critical. Klivira streamlines these intricate workflows, reducing administrative burden and accelerating patient access to essential therapies.

Biktarvy in the Context of Rheumatology Patient Care

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is an essential antiretroviral therapy for HIV. While not a rheumatology-specific medication, rheumatology patients may have HIV as a co-morbidity. Prior authorization for Biktarvy would typically be managed by the prescribing infectious disease specialist or primary care provider, adhering to HIV treatment guidelines rather than rheumatology-specific criteria.

Prior Authorization for Co-morbid Conditions in Rheumatology

Managing prior authorizations for patients with complex co-morbidities, such as HIV in a rheumatology patient, introduces distinct challenges. While rheumatology PA focuses on advanced therapies like biologics and JAK inhibitors per ACR guidelines, PAs for medications like Biktarvy demand adherence to infectious disease protocols. Klivira's platform is designed to manage diverse PA requirements across specialties, ensuring comprehensive support for complex patient profiles.

Key Documentation for Rheumatology-Specific PAs

  • Diagnosis documentation with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, modified New York or ASAS for AS, 2019 EULAR/ACR for SLE).
  • Disease activity assessment scores (e.g., DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE).
  • Documentation of prior conventional DMARD trial and response (or contraindication) per indication.
  • Evidence of step therapy compliance, including biosimilar substitution mandates where applicable.
  • Completion of required pre-initiation screenings (e.g., TB, hepatitis B/C, immunization status) for immunosuppressive biologics.
  • For JAK inhibitors, documentation of prior TNF inhibitor failure due to FDA boxed warning and CMS guidance considerations.

Overcoming Common Prior Authorization Denials in Rheumatology

  • Failure to document specific prior agent trial in the required step-therapy sequence.
  • Denial of brand TNF inhibitor when biosimilar substitution is mandated by payer policy.
  • Missing or insufficient documentation of disease activity scores (DAS28, CDAI, PASI, etc.).
  • Insufficient duration of conservative care or conventional DMARD trial as per payer requirements.
  • Incomplete or missing TB, hepatitis, or immunization screening documentation.
  • Request for off-indication use of a biologic without supporting payer-specific policy.

Klivira's Role in Streamlining Complex PA Workflows

Klivira's prior authorization automation platform integrates with EMRs and payer portals, providing a unified solution for managing diverse PA requirements. For rheumatology, this includes handling complex step therapy, biosimilar mandates, and re-authorization workflows for biologics. For medications like Biktarvy, Klivira supports the specific PA criteria and submission channels relevant to infectious disease protocols.

Integrated Solutions for Multi-Specialty Patient Populations

Our platform is engineered to navigate the complexities of multi-specialty patient care, from rheumatology's biologic-heavy PAs to infectious disease's antiretroviral requirements. By leveraging SMART on FHIR and X12 278 standards, Klivira ensures accurate data exchange and policy adherence, reducing administrative burden for your PA teams regardless of the prescribing specialty.

Frequently asked questions

Why would a rheumatology practice encounter prior authorization for Biktarvy?

While Biktarvy is an HIV medication, a rheumatology practice may encounter its prior authorization if a patient under their care for a rheumatologic condition also has HIV. In such cases, the PA for Biktarvy would typically be initiated by the infectious disease specialist or primary care provider, though the rheumatology team might coordinate care.

How does Klivira differentiate between rheumatology-specific PA criteria and other specialty medications?

Klivira's platform incorporates payer-specific policy logic that is aware of clinical guidelines like those from the ACR for rheumatology, as well as guidelines for other specialties. This allows our system to apply the correct documentation requirements, step therapy rules, and clinical criteria for each medication and indication, regardless of the prescribing specialty.

What are the primary PA challenges for biologics in rheumatology?

Rheumatology biologics face challenges including complex step therapy requirements, variable biosimilar substitution mandates across payers, chronic re-authorization burdens, and the need for detailed disease activity and screening documentation. Many payers also require specific TNF inhibitor failures before approving non-TNF biologics or JAK inhibitors.

Can Klivira manage re-authorizations for chronic rheumatology treatments?

Yes, Klivira's platform includes robust features for managing periodic re-authorizations common in chronic rheumatology treatments. Our system tracks re-authorization cycles, prompts for required updated documentation (e.g., disease activity scores), and automates the submission process to ensure continuous patient access to essential therapies.

How does Klivira handle the medical vs. pharmacy benefit split for specialty drugs?

Klivira's platform is designed to manage prior authorizations across both medical and pharmacy benefits. For specialty drugs often administered under both benefits depending on the payer and administration route, our system intelligently routes the PA request to the correct channel, ensuring compliance with benefit-specific requirements.

Related coverage

Other biktarvy prior authorization by payer

Other biktarvy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo